Onkologie. 2012:6(3):169-171

Hormone-refractory carcinoma and medication therapy

Jana Katolická
Onkologicko-chirurgické oddělení, FN u sv. Anny, Brno

Based on the results of the TAX 327 study, docetaxel has become the standard therapy in the first-line treatment of hormone-refractory prostate

cancer. A cytostatic drug for the second-line treatment of hormone-refractory prostate cancer has been established from the results of the

phase III TROPIC study in which the efficacy and safety of cabazitaxel in combination with prednisone was shown. Based on the results of recent

clinical trials, immunotherapy proved to be of value in the treatment of prostate cancer. Biosynthesis of extragonadal androgens may contribute

to the progression of castration-resistant prostate cancer; therefore, androgen-regulating enzyme inhibitors are useful in its treatment.

Keywords: chemotherapy, immunotherapy, androgen-regulating enzyme inhibition

Published: July 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J. Hormone-refractory carcinoma and medication therapy. Onkologie. 2012;6(3):169-171.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Tannock IF, de Wit R, Berrry WR, et al. Docetaxel plus prednison or mitoxantrone plus prednison for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. Go to original source... Go to PubMed...
    2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refraktory prostate cancer. N Engl J Med 2004; 351: 1513-1520. Go to original source... Go to PubMed...
    3. Zamdino MG, Verri E, et al. Vinorelbine-based Chemotherapy in Hormone-refractory Prostate Cancer. Anticancer Res 2006; 26: 2375-2380.
    4. de Bono JS, Oudard S, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancor progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154. Go to original source... Go to PubMed...
    5. Cha E, Fong L. Imunoterapie karcinomu prostaty: biologické a léčebné aspekty. JCO 2011; 3: 308-315 české vydání.
    6. de Bonno JS, Logothetis Ch J, et al. Abiraterone and Oncreased Survival in Metastatic Prostate Cancer. N Engl J Med 2011; 364: 1995-2005. Go to original source... Go to PubMed...
    7. Picus, Halabi S, Rini B, et al. The use ofbevacizumab (B) withdocetaxel (D) and estramustin on hormone refraktory prostate cancer (HRCP): Initialresultsof CALGB 90006. ProcAmClinOncol 2003; 22: 393.
    8. Sternberg CN, Dumez H, Van Poppel H, et al. Multicenter randomized EORTC trial 30021 of doceaxel + oblimersen and docetaxel in patients (pts) with hormone refraktory prostate cancer (HRCP). Proc ASCO Prostate Cancer Symp 2007 [abstr 144].
    9. Chi KN, Hotte SJ, Yu E, et al. A randomizedphase II. study of OGX-011in combination with docetaxel and prednison or docetaxel and prednisone alone in patiens with metastatic hormone refraktory prostate cancer (HRCP). J Clin Oncol 2007; 25(June 20 Suppl.) [abstr 5069]. Go to original source...
    10. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasetran on tumor progression in menwith hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J ClinOncol 2003; 21: 679-689. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.